Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- Status
- TERMINATED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
A Study of DF6002 Alone and in Combination With Nivolumab
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficiency and Security of NIVOLUMAB Therapy in Obese Individuals With COVID-19(COrona VIrus Disease) Infection
- Status
- UNKNOWN
- Phase
- PHASE2
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence
- Status
- TERMINATED
- Phase
- PHASE3
Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab + Ipilimumab + Radiation in MSS Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide
- Status
- WITHDRAWN
- Phase
- PHASE1
COVID-19: A Pilot Study of Adaptive Immunity and Anti-PD1
- Status
- UNKNOWN
- Phase
- PHASE2